Nina Shah


Multiple myeloma researcher and hematology events planner

Dr. Nina Shah is a specialist in blood diseases who focuses on treating multiple myeloma, a type of cancer affecting certain cells in the bone marrow. Her areas of professional interest include the intersection of immunology and oncology as well as helping patients fight multiple myeloma by boosting their immune systems.

Shah earned a bachelor's degree in cognitive neuroscience at Harvard University, followed by a medical degree from New York University School of Medicine. She completed a residency in internal medicine at Columbia University and a fellowship in hematology-oncology at the University of Texas MD Anderson Cancer Center.

Shah belongs to the American Society of Clinical Oncology, American Society of Hematology and American Society for Transplantation and Cellular Therapy. She speaks Bengali and Spanish.

  • Education

    New York University School of Medicine, 2002

  • Residencies

    Columbia University, Internal Medicine, 2005

  • Fellowships

    University of Texas MD Anderson Cancer Center, Hematology-Oncology, 2010

  • Board Certifications

    Hematology, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title


  • Languages




My goal is to see every encounter from the patient’s perspective. By imagining how others feel, I hope to treat the person, not just the patient.

Where I see patients (2)

    My reviews


    Overall Experience
    260 Ratings
    Explained things in a way that was easy to understand
    259 Ratings
    Did the doctor pay attention to your concerns
    258 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    250 Ratings
    Knew the important information about your medical history
    258 Ratings
    The provider showed respect for what you had to say
    258 Ratings
    The provider spent enough time with me
    257 Ratings
    Decorative Caduceus

    A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma


    Decorative Caduceus

    A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple M...

    DLTs will be assessed during the DLT interval (ie, within 21 days immediately after bb2121 infusion). DLTs are defined as any bb2121 related Grade 3 to 5 toxicity.


    Decorative Caduceus

    Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malig...

    Incidence of adverse events (AEs) observed across STRO-001 dose levels


    Decorative Caduceus

    Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refract...

    ORR is defined as stringent complete response (sCR) + complete response (CR) + very good partial response + partial response (PR) as best response using International Myeloma Working Group (IMWG) Uniform Response Criteria for all ...


    Decorative Caduceus

    A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or With...

    To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.